Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) posted its earnings results on Thursday. Here are the key takeaways from Xenon Pharmaceuticals’ conference call:Get Xenon Pharmaceuticals alerts:Atera demand significantly exceeded expectations , with booked orders already well above the approximately 40 instruments the company expects to ship in 2026. Xenon Pharmaceuticals Stock PerformanceXENE stock traded down $1.19 during midday trading on Friday, reaching $63.36. Xenon Pharmaceuticals Company Profile(Get Free Report)Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. Read MoreReceive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.